News

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.

Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.

Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.

Georg-August-University Göttingen and MRC Technology have signed an exclusive license agreement for the development of a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x. The aim is to develop a therapy for Alzheimer's Disease (AD).

BioCision and Cook ink exclusive deal to combine technologies to standardize cell cryopreservation in closed-system vials.

A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.

A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.

A special type of synthetic sugar could be the latest weapon in the fight against superbugs.